Kovack Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Kovack Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,200	Closed	-$51.3K	–	611
2023 Q3	$51.3K	Buy	+10,200	New	+$64.7K	0.01%	544

Other funds holding TERN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Kovack Advisors's TERN Position: Q4 2023 in Review

Kovack Advisors sold out of Terns Pharmaceuticals (TERN) in Q4 2023, closing a stake of 10,200 shares — an estimated $51.3K sold.

Kovack Advisors first reported a position in TERN in Q3 2023 and held it in 1 quarter. The position peaked at $51.3K in Q3 2023. 103 funds tracked by Wall St. Rank hold TERN as of Q4 2023.

Kovack Advisors reported no remaining Terns Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Kovack Advisors sold 10,200 Terns Pharmaceuticals shares in Q4 2023, an estimated $51.3K.
Kovack Advisors first reported a position in Terns Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Kovack Advisors's Terns Pharmaceuticals position peaked at $51.3K in Q3 2023.
103 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2023.

Based on Kovack Advisors's 13F filing for Q4 2023, filed 2 Feb 2024.